ASCO GU 2022 Highlights

CME

Key Studies in Urothelial, Prostate, and Kidney Cancer: CCO Independent Conference Highlights of the 2022 Genitourinary Cancers Symposium

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 18, 2022

Expiration: April 17, 2023

Toni K. Choueiri
Toni K. Choueiri, MD
Daniel P. Petrylak
Daniel P. Petrylak, MD

Activity

Progress
1
Course Completed
References

  1. Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022; [Epub ahead of print].
  2. Smith MR, Hussain MHA, Saad F, et al. Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial. Presented at: 2022 ASCO Genitourinary Cancers Symposium; February 17-19, 2022. Abstract 13.
  3. Fizazi K, Galceran JC, Foulon S, et al. A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1. Presented at: 2021 European Society for Medical Oncology Congress; September 16-21, 2021. Abstract LBA5_PR.
  4. Wang L, Paller C, Hong H, et al. Comparison of treatments for nonmetastatic castration-resistant prostate cancer: matching-adjusted indirect comparison and network meta-analysis. J Natl Cancer Inst. 2022;114:191-202.
  5. Lu-Yao G, Nikita N, Keith S, et al. Clinical outcomes among patients treated with abiraterone acetate for advanced prostate cancer with pre-existing cardiovascular conditions. Presented at: 2019 AACR Annual Meeting, March 29-April 3, 2019; Atlanta, GA. Abstract 4469.
  6. Saad F, Armstrong AJ, Thiery-Vuillemin A, et al. PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Presented at: 2022 ASCO Genitourinary Cancers Symposium; February 17-19, 2022. Abstract 11.
  7. Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al. PROPEL: A randomized, phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Presented at: 2019 ASCO Genitourinary Cancers Symposium; February 14-16, 2019. Abstract TPS340.
  8. Lozano R, Castro E, Aragón IM, et al. Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. Br J Cancer. 2021;124:552-563.
  9. Chi KN, Rathkopf DE, Raymond Smith M, et al. Phase 3 MAGNITUDE study: first results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. Presented at: 2022 ASCO Genitourinary Cancers Symposium; February 17-19, 2022. Abstract 12.
  10. Chi KN, Rathkopf DE, Attard G, et al. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. Presented at: 56th Annual Meeting of the American Society of Clinical Oncology; May 29-31, 2020. Abstract TPS5588.
  11. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: bladder cancer. v.1.2022. nccn.org. Accessed March 23, 2022.
  12. Pfister C, Gravis G, Fléchon A, et al. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG/AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses. Eur Urol. 2021;76:214-221.
  13. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859-866.
  14. Petrylak DP, Flaig TW, Mar N, et al. Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible. Presented at: 2022 ASCO Genitourinary Cancers Symposium; February 17-19, 2022. Abstract 435.
  15. Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384:1125-1135.
  16. Yu EV, Petrylak DP, O'Donnell PH, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021;22:872-882.
  17. Rosenberg JE, Hoon Park S, Dao TV, et al. BAYOU: A phase II, randomized, multicenter, double-blind study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC). Presented at: 2022 ASCO Genitourinary Cancers Symposium; February 17-19, 2022. Abstract 437.
  18. Crabb SJ, Hussain SA, Soulis E, et al. A randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS rucaparib arm. Presented at: 2022 ASCO Genitourinary Cancer Symposium; February 17-19, 2022. Abstract 436.
  19. Grivas P, Pouessel D, Park CH, et al. TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens. Presented at: 2022 ASCO Genitourinary Cancers Symposium; February 17-19, 2022. Abstract 434.
  20. Fradet Y, Bellmunt J, Vaughn DJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 2019;30:970-976.
  21. Choueiri TK, Tomczak P, Hoon Park S, et al. Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. Presented at: 2022 ASCO Genitourinary Cancers Symposium; February 17-19, 2022. Abstract 290.
  22. Choueiri TK, Tomczak P, Hoon Park S, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med. 2021;385:683-694.
  23. US Food and Drug Administration. FDA approves pembrolizumab for adjuvant treatment of renal cell carcinoma. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-adjuvant-treatment-renal-cell-carcinoma. Accessed March 17, 2022.
  24. Sharma E, Dahal S, Sharma P, et al. The characteristics and trends in adrenocortical carcinoma: a United States population based study. J Clin Med Res. 2018;10:636-640.
  25. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: neuroendocrine and adrenal tumors. v.4.2021. nccn.org. Accessed March 17, 2022.
  26. Tang Y, Liu Z, Zou Z, et al. Benefits of adjuvant mitotane after resection of adrenocortical carcinoma: a systematic review and meta-analysis. Biomed Res Int. 2018;2018:9362108.
  27. Berruti A, Fassnacht M, Libè R, et al. First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The AdIUVO study. Presented at: 2022 ASCO Genitourinary Cancers Symposium; February 17-19, 2022. Abstract 1.